NCT06009393已完成2 期
A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
Beijing Suncadia Pharmaceuticals Co., Ltd1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年12月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Percent change in calculated LDL-C from baseline to week 12
研究概览
简要总结
This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of functional HoFH by either genetic or clinical criteria as defined in the protocol
- •LDL-C ≥2.6mmol/L at the screening visit
- •Body weight ≥40 kg
- •Receiving stable lipid-lowering therapy for at least 28 days before enrollment.
排除标准
- •Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening (HbA1c > 8.5%)
- •eGFR <30ml/min/1.73m2 at the screening visit
- •CK >5times ULN at the screening visit
研究组 & 干预措施
SHR-1918
Experimental
干预措施: SHR-1918 (Drug)
结局指标
主要结局
Percent change in calculated LDL-C from baseline to week 12
时间窗: from baseline to week 12
次要结局
- Change in calculated LDL-C from baseline to week 12(from baseline to week 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)Homozygous Familial HypercholesterolemiaNCT03156621Regeneron Pharmaceuticals69
已完成
3 期
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaNCT03399786Regeneron Pharmaceuticals65
Unknown
不适用
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.HypercholesterolemiaNCT01982461Pin Siang Medical Biotechnology Co., Ltd.40
进行中（未招募）
2 期
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHDGraft Vs Host DiseaseNCT05621759NYU Langone Health27
招募中
2 期
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapyMetastatic Colorectal CancerNCT05962502Sun Yat-sen University54